piritrexim has been researched along with Carcinoma 256, Walker in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Duch, DS; Grivsky, EM; Lee, S; Nichol, CA; Sigel, CW | 1 |
| Bowers, SW; Duch, DS; Edelstein, MP; Nichol, CA | 1 |
2 other study(ies) available for piritrexim and Carcinoma 256, Walker
| Article | Year |
|---|---|
Synthesis and antitumor activity of 2,4-diamino-6-(2,5-dimethoxybenzyl)-5-methylpyrido[2,3-d]pyrimidine.
Topics: Animals; Antineoplastic Agents; Carcinoma 256, Walker; Cell Division; Folic Acid Antagonists; Humans; In Vitro Techniques; Leukemia, Myeloid; Male; Methotrexate; Pyrimidines; Rats | 1980 |
Biochemical and chemotherapeutic studies on 2,4-diamino-6-(2,5-dimethoxybenzyl)-5-methylpyrido[2,3-d]pyrimidine (BW 301U), a novel lipid-soluble inhibitor of dihydrofolate reductase.
Topics: Animals; Antineoplastic Agents; Biological Transport; Carcinoma 256, Walker; Drug Evaluation, Preclinical; Folic Acid Antagonists; Histamine N-Methyltransferase; Humans; Leukemia, Myeloid; Mice; Pyrimidines; Sarcoma 180; Structure-Activity Relationship | 1982 |